ModifiedmhnPolicy CP.PMN.27

Clinical Policy: Linezolid (Zyvox)

Criteria and requirements for medical necessity determination and prior authorization of linezolid (Zyvox) for Centene-affiliated health plans, including FDA-approved and certain off-label uses (MDR/XDR-TB). Applies to providers requesting coverage for members under the specified lines of business.

Policy Summary

Payermhn

PolicyClinical Policy: Linezolid (Zyvox)

Policy CodePolicy CP.PMN.27

Change TypeDose revisiongeneric substitution requirementstep therapy update

Effective DateSep 1, 2006

Next Review Date

Key ActionSubmit prior authorization with documentation (office notes, labs, C&S) showing member meets initial or continued therapy criteria; if requesting oral brand Zyvox, document use of generic linezolid first.

SourceLink

POLICY UPDATE CHANGES

In Section V MDR-TB or XDR-TB dosing, modified linezolid initial dose from 1,200 mg to 600 mg per CDC recommendations.

Added requirement that if request is for orally administered brand Zyvox, member must use generic linezolid.

Added references to generic linezolid in Policy/Criteria description and added step therapy bypass for IL HIM per IL HB 5395.

28 daysdefault maximum treatment duration (FDA)

1,200 mgmaximum daily dose

600 mgCDC-recommended initial dose (MDR/XDR-TB)

24 months

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Linezolid (Zyvox)

Initial Approval — All FDA-Approved Indications

Covered when ALL of the following are met

Initial FDA indications: 1) Diagnosis is an FDA-approved indication; 2) Member meets one of the following: a) Request is for continuation of therapy initiated in an acute care hospital from which member was discharged; OR b) Both of the following: i) Culture and sensitivity (C&S) report for the current infection shows the isolated pathogen is a gram-positive bacteria susceptible to linezolid, unless provider documents that obtaining a C&S report is not feasible; AND ii) One of: a) Failure of ≥ 2 formulary antibiotics to which the isolated pathogen is susceptible (if available) per C&S report, unless clinically significant adverse effects are experienced or all are contraindicated; b) C&S report shows resistance or lack of susceptibility of the isolated pathogen to all formulary antibiotics FDA-approved for the member's diagnosis; c) If provider documents that obtaining a C&S report is not feasible: failure of ≥ 2 formulary antibiotics indicated for the member's diagnosis (if available), unless clinically significant adverse effects are experienced or all are contraindicated; 3) If request is for orally administered brand Zyvox, member must use generic linezolid unless contraindicated or clinically significant adverse effects are experienced; 4) Dose does not exceed both: a) 1,200 mg per day; b) 2 tablets, 2 vials, or 60 mL suspension per day. Approval duration: Duration of request or up to 28 days of total treatment, whichever is less.

Initial Approval — Pulmonary MDR-TB and XDR-TB (off-label)

Covered when ALL of the following are met

MDR/XDR-TB initial: 1) Diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) or extensively drug resistant tuberculosis (XDR-TB); 2) Prescribed by or in consultation with an infectious disease specialist, pulmonologist, or tuberculosis treatment expert (e.g., state or county public health department, CDC-designated Centers of Excellence); 3) If request is for orally administered brand Zyvox, member must use generic linezolid unless contraindicated or clinically significant adverse effects are experienced; 4) Dose does not exceed both: a) 1,200 mg per day; b) 2 tablets per day. Approval duration per continued-therapy criteria if applicable.

Continued Therapy — All FDA-Approved Indications

Covered when ALL of the following are met

Continued FDA indications: 1) Member meets one of the following: a) Currently receiving medication via Centene benefit or previously met initial approval criteria; b) Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations; c) Request is for continuation of therapy initiated in an acute care hospital from which member was discharged; 2) Member is responding positively to therapy; 3) Member has not received ≥ 28 days of therapy for the current infection; 4) If request is for orally administered brand Zyvox, member must use generic linezolid unless contraindicated or clinically significant adverse effects are experienced; 5) If request is for a dose increase, the new dose does not exceed both: a) 1,200 mg per day; b) 2 tablets, 2 vials, or 60 mL suspension per day. Approval duration: Up to 28 days of total treatment.

Continued Therapy — Pulmonary MDR-TB and XDR-TB (off-label)

Covered when ALL of the following are met

MDR/XDR-TB continued: 1) Member meets one of the following: a) Currently receiving medication via Centene benefit or previously met initial approval criteria; b) Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations; 2) Member is responding positively to therapy; 3) If request is for orally administered brand Zyvox, member must use generic linezolid unless contraindicated or clinically significant adverse effects are experienced; 4) If request is for a dose increase, the new dose does not exceed both: a) 1,200 mg per day; b) 2 tablets per day. Approval duration: Up to a total treatment duration of 24 months.

MDR-TB / XDR-TB combination therapy

Dosage and administration guidance (includes MDR/XDR-TB regimens with pretomanid and Sirturo in DOT setting):

MDR/XDR-TB regimen (pediatrics and adults): Administer linezolid in combination with bedaquiline (Sirturo) and pretomanid in a directly observed therapy (DOT) setting; Sirturo: 400 mg PO once daily for the first 2 weeks, then 200 mg PO three times per week (with at least 48 hours between doses) for 24 weeks (total 26 weeks); Pretomanid: 200 mg PO once daily for 26 weeks; linezolid dosing per age group as stated in dosing section (infants/neonates: 10 mg/kg PO or IV every 8 hours; pediatric and adult regimens per Section V).

Dose limits and CDC-recommended initial dosing

Dose limits and adjustments:

Dose limits: Policy lists a maximum dose of 1,200 mg/day; however, the policy documents a revision per CDC recommending an initial dose of 600 mg/day for MDR/XDR-TB. Follow the CDC-recommended initial dosing for MDR/XDR-TB where applicable.max=1,200 mg/day; recommended initial=600 mg/day

Policy history documents change to 600 mg initial dose per 3Q 2023 review.

This policy does not authorize linezolid (Zyvox) for Gram-negative infections. Zyvox is not indicated for treatment of Gram-negative organisms and specific Gram-negative therapy should be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected. In addition, the safety and efficacy of Zyvox beyond 28 days for standard FDA indications have not been established; longer durations are addressed only where explicitly permitted by the MDR/XDR‑TB criteria in this policy.

Coding listed in this policy is provided for informational purposes only. The inclusion or exclusion of procedure or billing codes in this document does not by itself guarantee coverage or payment; providers must reference current professional coding guidance when submitting claims.

Use of linezolid for Gram-negative infections or for non‑FDA indications that are not expressly addressed in this policy is not authorized unless the request includes sufficient documentation of efficacy and safety per the referenced off‑label use policies. Requests lacking adequate off‑label justification or supporting clinical evidence may be denied.

The presence of a diagnosis or procedure code in this policy does not imply automatic coverage. Inclusion or exclusion of any codes does not guarantee coverage, and adjudication is subject to the plan’s medical necessity determinations and current coding rules.

Product Availability, Dosing Limits, and Codes

Product availabilitymixed

Tablet: 600 mg	product availability — tablet strength
Injection: 200 mg/100 mL, 600 mg/300 mL	product availability — injection
Oral suspension: 100 mg/5 mL	product availability — suspension

HCPCS Codes referencedHCPCS

J2020	Injection, linezolid, 200 mg
J2021	Injection, linezolid (Hospira) not therapeutically equivalent to J2020, 200 mg

inv-13: Maximum daily dose — 1,200 mg/day

Maximum daily dose1,200 mg/day

Dose cap per formulationNo more than 2 tablets, 2 vials, or 60 mL suspension per day

Approval duration impactDose limit applies to initial and continued therapy approvals (≤ 28 days for standard FDA indications)

inv-14: Standard maximum duration (FDA indications) — ≤ 28 days total treatment

Standard maximum total treatment duration (FDA indications)≤ 28 days of total treatment

Approval duration for initial requestsDuration of request or up to 28 days, whichever is less

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization is required and requests must meet the initial or continued therapy criteria listed in this policy. This includes submission of culture & sensitivity (C&S) data when available; if obtaining a C&S is not feasible, the provider must document why.

PA applies to all FDA-approved indications per the policy criteria
If C&S unobtainable, provider must document justification

Documentation Required

Required Documentation

Provider must submit supporting documentation (such as office chart notes, lab results, C&S reports, or other clinical information) showing the member meets all applicable criteria. Missing or incomplete documentation may result in denial.

Examples: office notes, lab results, C&S reports, hospital discharge summaries

Background on Linezolid

Linezolid is an oxazolidinone antibacterial indicated for certain gram‑positive infections, including nosocomial and community‑acquired pneumonia, complicated and uncomplicated skin and skin‑structure infections, and infections due to vancomycin‑resistant Enterococcus faecium. It should be reserved for infections proven or strongly suspected to be caused by susceptible bacteria, guided by culture and susceptibility data when available. Linezolid is not indicated for gram‑negative infections and prolonged use beyond 28 days for standard indications has not been evaluated in controlled trials; the policy provides specific criteria for authorized longer courses only in the context of MDR/XDR‑TB regimens.

Key Definitions and Regimens

inv-25: MDR-TB/XDR-TB laboratory confirmation — MDR-TB / XDR-TB

DefinitionMDR-TB: laboratory confirmation requires genotypic or phenotypic resistance to isoniazid and rifampin; XDR-TB: resistance to isoniazid, rifampin, fluoroquinolones, and second-line injectable agents

Laboratory confirmation methodsGenotypic or phenotypic testing can be used to demonstrate resistance

Source guidanceRefer to CDC and WHO guidance for diagnostic confirmation and management of drug-resistant TB

inv-26: BPaL — BPaL regimen definition

Regimen componentsBPaL = Bedaquiline (Sirturo) + Pretomanid + Linezolid

Pretomanid dosing within BPaLPretomanid: 200 mg PO once daily for 26 weeks